PRODUCTS

Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in more than 75 countries, we are proud to have reached millions of people with our products.

Do you want to link to this Other Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Repatha® Inj. Pre-filled pen

  • Product Name (Korean) 레파타®주 프리필드펜(에볼로쿠맙)
  • Product Name (English) Repatha® Inj. Pre-filled pen(evolocumab)
  • Active Ingredient (Korean) 에볼로쿠맙
  • Active Ingredient (English) evolocumab
  • API content 140 mg/1.0 mL
  • Excipients Proline, Acetic acid, glacial, Polysorbate 80, Sodium hydroxide, Water for injection, Sterilized needle
  • Treatment Anti-atherosclerotic agent
  • Indications
    1. Hypercholesterolemia and mixed dyslipidemia
      • THIS DRUG is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet
      - in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
      - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant
      • THIS DRUG is indicated in pediatric patients aged 10 years and over with heterozygous familial hypercholesterolemia (HeFH) as an adjunct to diet, in combination with other lipid-lowering therapies
    2. Homozygous Familial Hypercholesterolemia
      THIS DRUG is indicated in adults and pediatric patients aged 10 years and over with homozygous familial hypercholesterolemia (HoFH) in combination with other lipid-lowering therapies (e.g., statins, ezetimibe, LDL apheresis)
    3. Atherosclerotic cardiovascular disease
      THIS DRUG is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies
  • Product User Guide Repatha®  Inj. Pre-filled pen User Guide (Short Version)
    Repatha®  Inj. Pre-filled pen User Guide (Full Version)
    Repatha®  Inj. Pre-filled pen Product Information

    This video is intended to facilitate the safe and effective use of Repatha Inj. Pre-filled Pen, and to provide accurate information and education on the correct medication method. It is not intended as an advertisement. Reproducing or distributing this video to unspecified persons is prohibited. As this is a prescription drug, prescription and medication guidance by doctors and pharmacists must take precedence over this video, and we advise you to consult healthcare professionals.

    This video does not replace the product information and instructions for use. Please refer to the product information and instructions for use inserted in the product before using Repatha Inj. Pre-filled Pen.
  • Repatha® Product information

Lumakras® tablet 120mg 

  • Product Name (Korean) 루마크라스®정 120mg(소토라십)
  • Product Name (English) LUMAKRAS® tablet 120mg(sotorasib)
  • Active Ingredient (Korean) 소토라십
  • Active Ingredient (English) Sotorasib
  • API content 120mg
  • Excipients Microcrystalline cellulose, Lactose monohydrate, Croscarmellose sodium, Magnesium stearate, Opadry II Yellow(85F120132)
  • Treatment Anticancer
  • Indications

    Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one prior therapy

  • Lumakras® Product information

BLINCYTO® Inj. 35 μg

  • Product Name (Korean) 블린사이토®주 35μg(블리나투모맙)
  • Product Name (Engilsh) BLINCYTO®  Inj. 35μg(blinatumomab)
  • Active Ingredient (Korean) 블리나투모맙
  • Active Ingredient (English) blinatumomab
  • API content 35μg/1 vial
  • Excipients

    Citric Acid Monohydrate, Lysine Hydrochloride (stabilizer, 25.55 mg), Polysorbate 80, Trehalose Dihydrate (stabilizer, 105.0 mg), Sodium Hydroxide

    [IV Solution Stabilizer] 1 vial (10 mL) contains Citric Acid Monohydrate (52.5 mg), Lysine Hydrochloride (2283.8 mg), Polysorbate 80 (10 mg), Sodium Hydroxide (q.s.), Water For Injection (q.s.)

  • Treatment Anti-malignant tumor agent
  • Indications

    1. MRD-positive B-cell Precursor ALL
    THIS DRUG is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.

    2. Relapsed or Refractory B cell Precursor ALL
    THIS DRUG is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

  • BLINCYTO® Product information

XGEVA® Injection

  • Product Name (Korean) 엑스지바®주(데노수맙)
  • Product Name (English) Xgeva® Inj, (denosumab)
  • Active Ingredient (Korean) 데노수맙
  • Active Ingredient (English) denosumab
  • API content 120 mg/1.7 mL
  • Excipients Sorbitol, glacial acetic acid, sodium hydroxide, water for injection
  • Treatment Treatment of serious bone problems in patients with bone metastases from solid tumors and multiple myeloma.
  • Indications
    1. Reduction of the risk for developing skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. Skeletal-related events refers to pathological fractures, radiation to bone, spinal cord compression, and bone surgery.
    2. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  • XGEVA® Product information

Evenity® Inj. Pre-filled Syringe

  • Product Name (Korean) 이베니티®주 프리필드시린지(로모소주맙)
  • Product Name (English) Evenity® Inj. Pre-filled Syringe(romosozumab)
  • Active Ingredient (Korean) 로모소주맙
  • Active Ingredient (English) romosozumab
  • API content 105mg/1.17mL
  • Excipients Calcium acetate, Acetate acid, glacial, Sucrose, Polysorbate 20, Sodium hydroxide, Water for injection, Sterilized injection needle
  • Treatment Osteoporosis
  • Indications
    1. Treatment of osteoporosis in postmenopausal women at high risk of fracture.
    2. Osteoporosis in men at high risk of fracture to increase bone mass.
  • Evenity® Product information

KYPROLIS® Inj. 60mg, 30mg

  • Product Name (Korean) 키프롤리스®주 60mg, 키프롤리스®주 30mg(카르필조밉)
  • Product Name (English) Kyprolis®  Inj. 60mg, Kyprolis®  Inj. 30mg, (carfilzomib)
  • Active Ingredient (Korean) 카르필조밉
  • Active Ingredient (English) carfilzomib
  • API content 60 mg/vial, 30 mg/vial
  • Excipients Sulfobutylether Beta-cyclodextrin (SBECD), Anhydrous Citric Acid, Sodium Hydroxide
  • Treatment Treatment of multiple myeloma.
  • Indications For the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with:
    • Lenalidomide and dexamethasone, or
    • Dexamethasone, or
    • Daratumumab and dexamethasone.
  • KYPROLIS® Inj. 30mg, Product information
  • KYPROLIS® Inj. 60mg, Product information

Prolia® Pre-filled Syringe 

  • Product Name (Korean) 프롤리아® 프리필드시린지(데노수맙)
  • Product Name (English) Prolia® Pre-filled Syringe (denosumab)
  • Active Ingredient (Korean) 데노수맙
  • Active Ingredient (English) denosumab
  • API content 60 mg/1 mL
  • Excipients Sorbitol, glacial acetic acid, polysorbate 20, sodium hydroxide, water for injection, injection needle
  • Treatment Treatment of osteoporosis.
  • Indications
    1. Treatment of postmenopausal women with osteoporosis.
    2. Treatment to increase bone mass in men with osteoporosis.
    3. Treatment of Glucocorticoid-Induced Osteoporosis
    4. Treatment of bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    5. Treatment of bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
  • Prolia® Product information
PRODUCTS